SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by ...

Will Pharma Continue Efforts to Diversify Clinical Trials? The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ‘good ...

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy that affects women. PCOS is also a leading cause of infertility. Women with PCOS may present with obesity, amenorrhea ...

SAN DIEGO, CA, USA I March 5, 2025 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the ...